Protective efficacy of Marek's disease vaccines

Current Topics in Microbiology and Immunology

Volumn 255, Issue , 2000, Pages 57-90

  Witter, R L ^a  

^a AGRICULTURAL RESEARCH SERVICE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MATERNAL ANTIBODY; VIRUS VACCINE;

AGE; AVIAN LYMPHOMATOSIS HERPETOVIRUS; BIRD DISEASE; DRUG CLASSIFICATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; GENETIC RESISTANCE; GOOD MANUFACTURING PRACTICE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEROTYPE; TREATMENT FAILURE; TREATMENT PLANNING; VACCINATION; VACCINE PRODUCTION;

AGE FACTORS; ANIMALS; BIRDS; DISEASE OUTBREAKS; HERPESVIRUS 2, GALLID; MAREK DISEASE; MAREK DISEASE VACCINES; POULTRY; VACCINATION; VACCINES, ATTENUATED; VACCINES, SYNTHETIC;

AVES; HERPETOVIRUS; MARDIVIRUS;

EID: 0034533410     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Review

References (183)

1. Filtered air positive pressure (FAPP) brooding of broiler chickens
2. Age susceptibility of chickens to Marek's disease
3. Influence of turkey herpesvirus vaccination on the B-haplotype effect on Marek's disease resistance in 15. B-congcnic chickens
4. Serotype specificity of B-haplotype influence on the relative efficacy of Marek's disease vaccines
5. Augmentation of retrovirus-induced lymphoid leukosis by Marek's disease herpesviruses in white leghorn chickens
6. Infection studies on a reticuloendotheliosis virus contaminant of a commercial Marek's disease vaccine
7. Revaccination of chicks for Marek's disease at twenty-one days old
8. Marek's disease vaccines have to become more ellicacious
9. Recommendations for control in the production of Marek's disease vaccine
10. Biological properties of a number of Marek's discase virus isolates
11. Field trials with an attenuated cell associated vaccine for Marek's disease
12. The epizootiology of Marek's disease, 1. Incidence of antibody, viraemia and Marek's disease in six flocks
13. A quantitative sequential study of viraemia and neutralising antibody to HVT and MDV in a commercial flock vaccinated with HVT
14. Studies on genetic resistance to Marek's disease in the domestic chicken
15. Trials with Marck's disease vaccines prepared from a turkey herpes virus and an attenuated Marek's disease virus
16. Effect of passively transferred immunoglobulins on Marek's disease
17. Behaviour of a very virulent Marck's disease virus in two vaccinated commercial chicken flocks in Argentina
18. Further characteristics of the CVI988 strain of Marek's disease virus
19. Immunological effects of reticuloendotheliosis virus as potential contaminant of Marek's disease vaccines
20. Early mortality syndrome of chickens after dual infection with Marek's disease virus (MDV) and chicken anaemia agent (CAA)
21. Effects of passive antibody on early pathogenesis of Marek's disease
22. Influence of age at exposure on the pathogenesis of Marek's disease
23. Comparative pathogenesis studies with oncogenic and nononcogenic Marek's disease viruses and turkey herpesvirus
24. Field trials with a bivalent vaccine (HVT and SB-1) against Marek's disease
25. Latent infections with Marek's disease virus and turkey herpesvirus
26. Vaccination against Marek's disease with cell-free turkey herpesvirus: Interference by maternal antibody
27. Dual virus maturation of both pathogenic and apathogenic Marek's disease herpesvirus (MDHV) in the feather follicles of dually infected chickens
28. Marek's disease vaccine breaks: Differences in viremia of vaccinated chickens between those with and without Marek's disease
29. Isolation and characterization of an isolate (HN) of Marek's disease virus with low pathogenicity
30. Development of neuralising antibody to turkey herpesvirus (HVT) in chickens with and without homologous maternal antibody
31. The effect of maternal antibody on Marek's disease
32. Production of vaccines
33. Virus effect of lyophilized turkey herpesvirus - Marek's vaccines in chicks with maternal antibodies against turkey herpesvirus
34. The attenuation with loss of oncogenicity of the herpes-type virus of Marek's disease (Strain HPRS-16) on passage in cell culture
35. Immunization against Marck's disease using a live attenuated virus
36. Studies on genetic resistance to Marek's disease
37. Vaccination of broilers with HVT expressing an Eimeria acervulina antigen improves performance after challenge with Eimeria
38. Herpesvirus of turkey recombinant viruses expressing infectious bursal disease virus (IBDV) VP2 immunogen induce protection against an IBDV virulent challenge in chickens
39. Protective efficacy of Marek's disease virus (MDV) CVI-988 CEF65 clone C against challenge infection with three very virulent MDV strains
40. Comparative 50% protective dose assays (PD 50) of Marek's disease virus strain CVI988
41. Marek's disease vaccination strategies using vaccines made front three avian herpesvirus serotypes
42. Possible horizontal spread of lymphoid leukosis virus during vaccination against Marek's disease
43. Resistance of progeny from parental stock of chickens immunized against Marek's disease
44. Efficacy Of cell-free and cell-associated herpesvirus of turkey vaccines in progeny from vaccinated parental flocks
45. Long term studies comparing the efficacy of cell-free versus cell-associated HVT vaccines against Marek's disease
46. Effectiveness of cell-free or cell-associated turkey herpesvirus vaccine against Marek's disease in chickens as influenced by maternal antibody, vaccine dose, and time of exposure to Marek's disease virus
47. Live recombinant vaccines for poultry
48. Marek's disease vaccines cause temporary B-lymphocyte dysfunction and reduced resistance to infection in chicks
49. In ovo vaccination of specific-pathogen-free chickens with vaccines containing multiple agents
50. Vaccination against Marek's disease: Effectiveness of cell associated and lyophilized herpesvirus of turkeys in 9 strains of leghorns
51. The effect of MHC on resistance to Marek's disease in White Leghorn crosses
52. Differences in susceptibility to Marek's disease in chickens carrying two different B locus blood group alleles
53. Onset of protective immunity in chicks after vaccination with a recombinant herpesvirus of turkeys vaccine expressing Newcastle disease virus fusion and hemagglutinin-neuraminidase antigens
54. Multiple causes of Marek's disease vaccination failure in Australian poultry flocks
55. Quality assurance of Marek's disease vaccine use in hatcheries
56. A study of vaccination against Marek's disease with an attenuated Marek's discase virus
57. Infectivity and immunogenicity of apathogenic and attenuated Marek's disease virus vaccines
58. Effects of infectious bursal disease on Marek's disease vaccination: Suppression of antiviral immune response
59. Chicken anaemia virus influences the pathogenesis of Marek's disease in experimental infections, depending on the dose of Marek's disease virus
60. Applications in ovo technology
61. Recombinant fowlpox viruses coexpressing chicken type I IFN and Newcastle disease virus HN and F genes: Influence of IFN on protective efficacy and humoral responses of chickens following in ovo or post-hatch administration of recombinant viruses
62. A herpesvirus isolated from kidney cell culture of normal turkeys
63. Difference between influences of homologous and heterologous maternal antibodies on response to serotype-2 and serotype-3 Marek's disease vaccines
64. Marek's disease virus and herpesvirus of turkey noninfective to chickens, obtained by repeated in vitro passages
65. Industry concerns workshop
66. A global perspective on Marek's disease control in layers and layer breeders
67. Marek's disease: Clinical aspects and current field problems in layer chickens
68. Isolation of highly lyric serotype 1 Marek's disease viruses from recent field outbreaks in Europe
69. HVT-viraemia and protection against Marek's disease following intramuscular or subcutaneous vaccination with different viral doses as well as following thermal stress broiler chicks
70. Marek's disease virus DNA in a chicken lymphoblastoid cell line (MSB-I) and in virus-induced tumours
71. Suppression and enhancement of mitogen response in chickens infected with Marek's disease virus and the herpesvirus of turkeys
72. Primary studies on immunoprotectivity of Marek's disease virus DNA vaccine
73. First isolation and characterization of very virulent Marek's disease virus in Taiwan
74. Characterization of very virulent strains of Marek's disease virus from vaccinated chickens in Eastern China
75. Impact of vv Marek's disease on mortality and production in a multiple-age farm
76. Field trials with an attenuated Marek's disease vaccine
77. Recent advances in filtered-air positive-pressure (FAPP) housing for the production of disease-free chickens
78. Efficacy in chickens of a herpesvirus of turkeys recombinant vaccine containing the fusion gene of Newcastle disease virus: Onset of protection and effect of maternal antibodies
79. Protection of chickens from Newcastle and Marck's diseases with a recombinant herpesvirus of turkeys vaccine expressing the Newcastle disease virus fusion protein
80. Marek's disease virus gC and meq mutants with dramatic reductions in tumour incidences and horizontal transmission
81. Protection against Newcastle Disease by recombinant Marek's disease virus scrotype-1 expressing the fusion protein of Newcastle Disease virus
82. Production of Marek's Disease vaccine
83. Attenuation of Marek's disease virus and study of its properties in two different cell cultures
84. Studies on intracellular and membrane antigens induced by Marek's disease virus
85. Protection against Marek's Disease by a fowlpox virus recombinant expressing the glycoprotein B of Marek's Disease virus
86. Protection and synergism by recombinant fowl pox vaccines expressing genes from Marek's disease virus
87. Comparison of intramuscular and subcutaneous administration of Marek's disease vaccine
88. The temporal relationship between vaccination with the herpesvirus of turkeys and challenge with virulent Marek's disease virus
89. Protection against Marek's disease by vaccination with a herpesvirus of turkeys
90. Partial protection against Marek's disease in chickens immunized with glycoproteins gB purified from turkey-herpesvirus-infected cells by affinity chromatography coupled with monoclonal antibodies
91. Depression of vaccinal immunity to Marek's disease by infection with chicken anaemia agent
92. Marek's disease
93. Course of infection in tissue of susceptible chickens after exposure to strains of Marek's disease and turkey herpesvirus
94. Pathogenicity studies with plaque-purified preparations of Marek's disease virus strain CVI-988
95. Effect of maternal antibody on viraemic and antibody responses to cell associated and cell free turkey herpesvirus in chickens
96. Efficacy of bivalent vaccine against Marek's disease
97. Public health concerns from human exposure to oncogenic avian herpesviruses
98. Marek's disease virus (MDV) antigens in the feather follicle epithelium: Difference between oncogenic and nononcogenic MDV
99. Embryo vaccination of turkeys against Newcastle disease infection with recombinant fowlpox virus constructs containing interferons as adjuvants
100. Protective efficacy of a recombinant herpesvirus of turkeys as an in ovo vaccine against Newcastle and Marek's diseases in specific pathogen-free chickens
101. In ovo vaccination technology
102. Herpes virus of turkey vaccine: Viraemias in field flocks and in experimental chickens
103. Control of Marek's disease in the Netherlands. II. Field trials on vaccination with an avirulent strain (CVI 988) of Marek's disease virus
104. Control of Marek's disease in the Netherlands. I. Isolation of an avirulent Marek's disease virus (strain CVI 988) and its use in laboratory vaccination trials
105. Reovirus interference with Marek's disease vaccination
106. Epizootiology and adult transmission of Marek's disease
107. Recombinant vaccines against Marek's disease
108. Use of Marek's vaccines - Protecting our future
109. The effect of maternal antibody against lyophilized Marek's disease live vaccine (Cell-free HVT)
110. Field trial and immunogenicity studies on the polyvalent Marek's disease vaccines in chickens
111. What to do if there is a Marek's disease problem?
112. Characterization of an apparently nononcogenic Marek's disease virus
113. Characterization of two highly oncogenic strains of Marek's disease virus
114. Pathogenesis of infection with attenuated Marek's disease virus strains
115. Induction of glycoprotein B (gB)-specific cytotoxic T cells after vaccination with recombinant fowl poxvirus expressing gB
116. Effectiveness of Riems MD (Marek's disease) vaccine on laying hens with different virus levels per immunization dose
117. Effect of infectious bursal disease virus on protection against Marek's disease by turkey herpesvirus vaccine
118. Delayed replication of Marek's disease virus following in ovo inoculation during late stages of embryonal development
119. Resistance to Marek's disease at hatching in chickens vaccinated as embryos with the turkey herpesvirus
120. Effect of in vitro adaptation of Marek's disease virus on pock induction on the chorioallantoic membrane of embryonated chicken eggs
121. Influence of maternal antibody on efficacy of embryo vaccination with cell-associated and cell-free Marek's disease vaccine
122. Comparative viral, immunologic and pathologic responses of chickens inoculated with herpesvirus of turkeys as embryos or at hatch
123. Embryo vaccination against Marek's disease with serotypes 1, 2 and 3 vaccines administered singly or in combination
124. Avian herpesvirus as a live viral vector for the expression of heterologous antigens
125. Expression of the NDV-F gene under the control of MDV1-GB promoter in recombinant MDV1
126. Attenuated Marek's disease herpesvirus: Protection conferred on strains of chickens varying in genetic resistance
127. Influence of maternal antibody on infection with virulent or attenuated Marek's disease herpesvirus
128. Quality control and standardization of vaccines
129. Protection of chickens against very virulent infectious bursal disease virus (IBDV) and Marek's disease virus (MDV) with a recombinant MDV expressing IBDV VP2
130. 2 intercross chickens
131. Should we vaccinate intramuscularly or subcutaneously?
132. Pathogenicity of an unusual highly virulent Marek's disease virus isolated in the United Kingdom
133. Vaccination tests against Marek's disease by application of an attenuated Marek herpes virus and a herpes virus of turkeys
134. Vaccination experiments against Marek's disease by application of an attenuated Marek herpesvirus and a turkey herpesvirus
135. Experiences with monovalent and bivalent Marek's disease vaccines
136. The influence of maternally derived HVT-neutralizing antibody on Marek's disease
137. Comparative evaluation of vaccines with turkey herpesvirus and Marek's disease virus strain CVI-988 in field trials in East Germany
138. Marek's disease. Study on the efficacy of three vaccines
139. Protection by attenuated and polyvalent vaccines against highly virulent strains of Marek's disease virus
140. Characteristics of Marek's disease viruses isolated from vaccinated commercial chicken flocks: Association of viral pathotype with lymphoma frequency
141. Association in broiler chickens between natural serotype 2 Marek's disease virus infection and leukosis condemnations
142. Principles of vaccination
143. Review: Vaccines and vaccination against Marek's disease
144. New serotype 2 and attenuated scrotype 1 Marek's disease vaccine viruses: Comparative efficacy
145. Protective synergism among Marek's disease vaccine viruses
146. Attenuated revertant serotype 1 Marek's disease viruses: Safety and protective efficacy
147. Influence of serotype and virus strain on synergism between Marek's disease vaccine viruses
148. Safety and comparative efficacy of the CVI988/Rispens vaccine strain
149. Attenuation of lymphoid leukosis enhancement by scrotype 2 Marek's disease virus
150. Increased virulence of Marek's disease virus field isolates
151. Control strategies for Marek's disease: A perspective for the future
152. Reproducibility of Efficacy tests for Marek's Disease Vaccines
153. Differential effect of maternal antibodies on efficacy of cellular and cell-free Marek's disease vaccines
154. An acute form of transient paralysis induced by highly virulent strains of Marek's disease virus
155. Poultry vaccines of the future
156. Polyvalent Marek's disease vaccines: Safety, efficacy and protective synergism in chickens with maternal antibodies
157. Depression of vaccinal immunity to Marek's disease by infection with reticuloendotheliosis virus
158. Characteristics of CVI988/Rispens and R2/23, two prototype vaccine strains of serotype 1 Marek's disease virus
159. Biological diversity among serotype 2 Marek's disease viruses
160. Retroviral insertional mutagenesis of a herpesvirus: A Marek's disease virus mutant attenuated for oncogenicity but not for immunosuppression or in vivo replication
161. Studies on the epidemiology of Marek's disease herpesvirus in broiler flocks
162. Isolation from turkeys of a cell-associated herpesvirus antigenically related to Marek's disease virus
163. Duration of vaccinal immunity against Marek's disease
164. Nonprotective and temperature-sensitive variants of Marek's disease vaccine viruses
165. Pathogenicity of variant Marek's disease virus isolants in vaccinated and unvaccinated chickens
166. Field trials to test the efficacy of polyvalent Marek's disease vaccines in broilers
167. Turkey herpesvirus infection in chickens: Induction of lymphoproliferative lesions and characterization of vaccinal immunity against Marek's disease
168. An age-related resistance of chickens to Marek's disease: Some preliminary observations
169. New serotype 2 and attenuated serotype 1 Marek's disease vaccine viruses: Selected biological and molecular characteristics
170. Experimental infection of turkeys and chickens with herpesvirus of turkeys (HVT)
171. High resolution mapping and identification of new quantitative trait loci (QTL) affecting susceptibility to Marek's disease
172. Dose effect of herpesvirus of turkeys on protection of chickens from Marek's disease
173. Contamination of Marek's disease vaccine with REV group of virus
174. Head start and concurrent infection of a small percentage of birds with a naturally occurring mild Marek's disease virus to reduce "Leukosis" condemnations in broilers
175. Marek's disease immunization procedures
176. The use of blood from selected chickens as an immunizing agent for Marek's disease
177. Partial flock inoculation with a apathogenic strain of chicken herpes virus of Marek's disease to immunize chicken flocks against pathogenic field strains of MD
178. Attenuation of the pathogenicity of Marek's disease virus
179. Marek's disease control: Comparative efficacy of cell-associated and cell-frec lyophilized HVT vaccine
180. Polyvalent vaccines for control of Marek's disease
181. Influence of strain of chickens on the immune response to vaccination against Marek's disease
182. Structure and properties of a herpesvirus of turkeys recombinant in which US1, US10 and SORF3 genes have been replaced by a lacZ expression cassette
183. Response of chicks from vaccinated hens to inoculation with turkey herpesvirus